XORTX Therapeutics Inc. (XRTX) stock
XRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $116.17KP/E –Yield –
XORTX Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2021 it was C$853.12K, up 207.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | C$853.12K | +207.5% |
| FY2020 | Dec 31, 2020 | C$277.46K | +595.4% |
| FY2019 | Dec 31, 2019 | C$39.90K | – |
See a number that looks wrong?